Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
Go back to Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital| (NASDAQ: ALZN) | Delayed: 1.21 +0.06 (5.22%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.15 | 52 Week High | $ | |||
| Open | $1.13 | 52 Week Low | $ | |||
| Day High | $1.24 | P/E | N/A | |||
| Day Low | $1.13 | EPS | $ | |||
| Volume | 61,212 | |||||
